Cargando…
Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?
A very recent epidemiological study provides preliminary evidence that living in habitats located at 2500 m above sea level (masl) might protect from the development of severe respiratory symptoms following infection with the novel SARS-CoV-2 virus. This epidemiological finding raises the question o...
Autores principales: | Soliz, Jorge, Schneider-Gasser, Edith M., Arias-Reyes, Christian, Aliaga-Raduan, Fernanda, Poma-Machicao, Liliana, Zubieta-Calleja, Gustavo, Furuya, Werner I., Trevizan-Baú, Pedro, Dhingra, Rishi R., Dutschmann, Mathias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275159/ https://www.ncbi.nlm.nih.gov/pubmed/32522574 http://dx.doi.org/10.1016/j.resp.2020.103476 |
Ejemplares similares
-
Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude?
por: Arias-Reyes, Christian, et al.
Publicado: (2020) -
Decreased incidence, virus transmission capacity, and severity of COVID-19 at altitude on the American continent
por: Arias-Reyes, Christian, et al.
Publicado: (2021) -
The role of glycinergic inhibition in respiratory pattern formation and cardio-respiratory coupling in rats
por: Furuya, Werner Issao, et al.
Publicado: (2021) -
Genetic variants of erythropoietin (EPO) and EPO receptor genes in familial erythrocytosis
por: Vočanec, Danijela, et al.
Publicado: (2018) -
Erythropoietin (EPO) in acute kidney injury
por: Moore, Elizabeth, et al.
Publicado: (2011)